Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int 2019;39:1468-1477. [PMID: 30963691 DOI: 10.1111/liv.14113] [Citation(s) in RCA: 106] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 03/22/2019] [Accepted: 03/28/2019] [Indexed: 02/13/2023]

For:	Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int 2019;39:1468-1477. [PMID: 30963691 DOI: 10.1111/liv.14113] [Citation(s) in RCA: 106] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 03/22/2019] [Accepted: 03/28/2019] [Indexed: 02/13/2023]

Number

Cited by Other Article(s)

101

Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol 2020;72:342-352. [PMID: 31954496 DOI: 10.1016/j.jhep.2019.09.010] [Citation(s) in RCA: 261] [Impact Index Per Article: 52.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Revised: 08/29/2019] [Accepted: 09/10/2019] [Indexed: 12/12/2022]

102

Kojima H, Nakamura K, Kupiec-Weglinski JW. Therapeutic targets for liver regeneration after acute severe injury: a preclinical overview. Expert Opin Ther Targets 2020;24:13-24. [PMID: 31906729 DOI: 10.1080/14728222.2020.1712361] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]

103

Zhang CH, Li M, Lin YP, Gao Q. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Curr Gene Ther 2020;20:84-99. [PMID: 32600231 DOI: 10.2174/1566523220666200628014530] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/26/2020] [Accepted: 05/28/2020] [Indexed: 12/24/2022]

104

Mazza G, Telese A, Al-Akkad W, Frenguelli L, Levi A, Marrali M, Longato L, Thanapirom K, Vilia MG, Lombardi B, Crowley C, Crawford M, Karsdal MA, Leeming DJ, Marrone G, Bottcher K, Robinson B, Del Rio Hernandez A, Tamburrino D, Spoletini G, Malago M, Hall AR, Godovac-Zimmermann J, Luong TV, De Coppi P, Pinzani M, Rombouts K. Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition. Cells 2019;9:83. [PMID: 31905709 PMCID: PMC7017194 DOI: 10.3390/cells9010083] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 12/23/2019] [Accepted: 12/24/2019] [Indexed: 12/12/2022] Open

Abstract

An altered liver microenvironment characterized by a dysregulated extracellular matrix (ECM) supports the development and progression of hepatocellular carcinoma (HCC). The development of experimental platforms able to reproduce these physio-pathological conditions is essential in order to identify and validate new therapeutic targets for HCC. The aim of this work was to validate a new in vitro model based on engineering three-dimensional (3D) healthy and cirrhotic human liver scaffolds with HCC cells recreating the micro-environmental features favoring HCC. Healthy and cirrhotic human livers ECM scaffolds were developed using a high shear stress oscillation-decellularization procedure. The scaffolds bio-physical/bio-chemical properties were analyzed by qualitative and quantitative approaches. Cirrhotic 3D scaffolds were characterized by biomechanical properties and microarchitecture typical of the native cirrhotic tissue. Proteomic analysis was employed on decellularized 3D scaffolds and showed specific enriched proteins in cirrhotic ECM in comparison to healthy ECM proteins. Cell repopulation of cirrhotic scaffolds highlighted a unique up-regulation in genes related to epithelial to mesenchymal transition (EMT) and TGFβ signaling. This was also supported by the presence and release of higher concentration of endogenous TGFβ1 in cirrhotic scaffolds in comparison to healthy scaffolds. Fibronectin secretion was significantly upregulated in cells grown in cirrhotic scaffolds in comparison to cells engrafted in healthy scaffolds. TGFβ1 induced the phosphorylation of canonical proteins Smad2/3, which was ECM scaffold-dependent. Important, TGFβ1-induced phosphorylation of Smad2/3 was significantly reduced and ECM scaffold-independent when pre/simultaneously treated with the TGFβ-R1 kinase inhibitor Galunisertib. In conclusion, the inherent features of cirrhotic human liver ECM micro-environment were dissected and characterized for the first time as key pro-carcinogenic components in HCC development.

Collapse

Affiliation(s)

Giuseppe Mazza Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Andrea Telese Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Walid Al-Akkad Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Luca Frenguelli Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Ana Levi Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Martina Marrali Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Lisa Longato Engitix Ltd., London NW3 2PF, UK;
Kessarin Thanapirom Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Maria Giovanna Vilia Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Benedetta Lombardi Proteomics and Molecular Cell Dynamics, Centre for Nephrology, School of Life and Medical Sciences, University College London, London NW3 2PF, UK; (B.L.); (M.C.); (J.G.-Z.)
Claire Crowley Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme, UCL Institute for Child Health, Great Ormond Street Hospital, University College London, London WC1N 3JH, UK; (C.C.); (P.D.C.)
Mark Crawford Proteomics and Molecular Cell Dynamics, Centre for Nephrology, School of Life and Medical Sciences, University College London, London NW3 2PF, UK; (B.L.); (M.C.); (J.G.-Z.)
Morten A. Karsdal Nordic Bioscience, Biomarkers & Research, Herlev Hovedgade 205-207, 2730 Herlev, Denmark; (M.A.K.); (D.J.L.)
Diana J. Leeming Nordic Bioscience, Biomarkers & Research, Herlev Hovedgade 205-207, 2730 Herlev, Denmark; (M.A.K.); (D.J.L.)
Giusi Marrone Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Katrin Bottcher Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Benjamin Robinson Department of Bioengineering, Cellular and Molecular Biomechanics, Imperial College, London SW7 2AZ, UK; (B.R.); (A.D.R.H.)
Armando Del Rio Hernandez Department of Bioengineering, Cellular and Molecular Biomechanics, Imperial College, London SW7 2AZ, UK; (B.R.); (A.D.R.H.)
Domenico Tamburrino Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Gabriele Spoletini Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Massimo Malago Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)
Andrew R. Hall Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.) Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London NW3 2PF, UK
Jasminka Godovac-Zimmermann Proteomics and Molecular Cell Dynamics, Centre for Nephrology, School of Life and Medical Sciences, University College London, London NW3 2PF, UK; (B.L.); (M.C.); (J.G.-Z.)
Tu Vinh Luong Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.) Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London NW3 2PF, UK
Paolo De Coppi Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme, UCL Institute for Child Health, Great Ormond Street Hospital, University College London, London WC1N 3JH, UK; (C.C.); (P.D.C.) Specialist Neonatal and Paediatric Surgery at Great Ormond Street Hospital, London WC1N 3JH, UK
Massimo Pinzani Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.) Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London NW3 2PF, UK
Krista Rombouts Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK; (A.T.); (W.A.-A.); (L.F.); (A.L.); (M.M.); (K.T.); (M.G.V.); (G.M.); (K.B.); (D.T.); (G.S.); (M.M.); (A.R.H.); (T.V.L.); (M.P.)

Collapse

105

Noonan A, Pawlik TM. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opin Investig Drugs 2019;28:941-949. [DOI: 10.1080/13543784.2019.1677606] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]

106

Da Fonseca LG, Wörns MA. The alpha and ßeta in phase II trials hepatocellular carcinoma - A tale of more than radiological response? Liver Int 2019;39:1391-1393. [PMID: 31368228 DOI: 10.1111/liv.14157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 05/22/2019] [Accepted: 05/23/2019] [Indexed: 02/13/2023]